Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CXCR4 Modified CD19 CAR-T in Relapsed/Refractory B-cell Malignancies
NCT04684472Phase 1Unknown
- Start
- Mar 2021
- Primary completion
- Jan 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cxcr4-modified anti-cd19 car t cells in B cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma. Primary endpoints: Incidence of treatment-emergent adverse events up to 5 years and Dose-limiting toxicity at 28 days. Status: unknown.
02
Drugs
cxcr4-modified anti-cd19 car t cells
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04684472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04684472.